AbbVie (ABBV) on Thursday said that Canada's Drug Agency (CDA-AMC) has recommended ELAHERE for reimbursement with conditions for the treatment of patients with certain types of platinum-resistant ovarian cancer.
The company noted that ELAHERE was submitted for reimbursement review 180 days before Health Canada's approval, in alignment with CDA-AMC's Target Zero initiative, which aims to accelerate patient access to new therapies.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.